BlossomHill Therapeutics, Inc. (BLSM) vs Ironwood Pharmaceuticals, Inc. (IRWD)
A side-by-side comparison of BlossomHill Therapeutics, Inc. and Ironwood Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
BLSM
BlossomHill Therapeutics, Inc.
$18.85HealthcareDelayed quote: Oct 6, 2026, 12:25 PM EDT
IRWD
Ironwood Pharmaceuticals, Inc.
$3.64HealthcareDelayed quote: Oct 6, 2026, 12:25 PM EDT
Total return — BLSM vs IRWD
growth of $100 · dividends reinvested · last 1yBLSM +24.6% (+24.6%/yr)IRWD -12.0% (-12.0%/yr)BLSM compounded faster over this window
BLSM IRWD
BLSM vs IRWD: by the numbers
- •IRWD is the larger company ($599M vs $548M market cap).
- •IRWD is profitable (33.36% net margin) while BLSM runs a net loss (0.00%).
Metrics side by side
Valuation
| Metric | BLSM | IRWD |
|---|---|---|
| P/E ratio | N/A | 4.74 |
| Forward P/E | N/A | 2.98 |
| P/S ratio | N/A | 1.54 |
| EV / EBITDA | N/A | 3.85 |
| FCF yield | N/A | 30.97% |
Profitability
| Metric | BLSM | IRWD |
|---|---|---|
| Gross margin | 0.00% | 99.76% |
| Operating margin | 0.00% | 40.10% |
| Net margin | 0.00% | 33.36% |
| ROIC | -43.41% | 58.60% |
Growth (annualized)
| Metric | BLSM | IRWD |
|---|---|---|
| Revenue CAGR (5Y) | N/A | -1.18% |
| EPS CAGR (5Y) | N/A | -25.87% |
| FCF CAGR (5Y) | N/A | -3.98% |
| Total return CAGR (5Y) | N/A | -22.82% |
Frequently asked
- Is BLSM or IRWD more profitable?
- IRWD runs the higher net margin — BLSM at 0.00% versus IRWD at 33.36%.
Go deeper
Dig into the metrics
Ironwood Pharmaceuticals P/E ratioBlossomHill Therapeutics ROEIronwood Pharmaceuticals ROEBlossomHill Therapeutics operating marginIronwood Pharmaceuticals operating marginBlossomHill Therapeutics revenue growthIronwood Pharmaceuticals revenue growthBlossomHill Therapeutics free cash flowIronwood Pharmaceuticals free cash flow
BlossomHill Therapeutics & Ironwood Pharmaceuticals appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.